Mar 28, 2017 - Novo Nordisk A/S (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP), has issued a positive opinion suggesting an update to the label for Tresiba (insulin degludec) to include data from the SWITCH studies.
Apr 10, 2017 - Merck announced that the FDA has denied approval to include cardiovascular outcomes data on the labels of its diabetes drug, Januvia (sitagliptin) and other medicines containing Januvia.
May 24, 2017 - Campbell, CA -based VIVUS, Inc. (VVUS) is a biopharmaceutical company developing and commercializing innovative, next-generation therapies to address unmet medical needs
May 24, 2017 - AstraZeneca plc (AZN) announced top-line results from the EXSCEL study evaluating the cardiovascular (CV) safety profile of its type II diabetes drug Bydureon.
Jun 14, 2017 -
Novo Nordisk A/S NVO announced positive results from the post-hoc analysis of the cardiovascular (CV) outcomes study, LEADER on Victoza.
Jun 10, 2017 - Traders cheered the company's first quarter earnings report.
Aug 14, 2017 - A solid-enough second quarter from the diabetes specialist boosts investors' confidence in a turnaround.
Aug 22, 2017 - Pfizer, GlaxoSmithKline, and Novo Nordisk all offer up temptingly high yields. Here's why they're worth putting on your radar.
Aug 09, 2017 - Novo Nordisk A/S (NYSE:NVO) Q2 2017 Earnings Conference Call August 9, 2017 7:00 AM ET Executives Lars Fruergaard Jorgensen – President and Chief Executive Officer Mads Krogsgaard Thomsen – Executive
Nov 07, 2017 - It was another lackluster quarter from the diabetes specialist.